Pfizer’s $43 billion acquisition of cancer and antibody-drug conjugate biotech Seagen has received all regulatory approvals and will close on Dec. 14, the biopharma giant announced on Tuesday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,